Gladstone’s Seth Shipman Named Fellow of the California Academy of Sciences
Shipman is recognized for pioneering molecular technologies that record cellular activity, expand genome editing, and target antibiotic-resistant superbugs.
Licensing
Gladstone maintains an active and diverse intellectual property (IP) portfolio around technologies, novel approaches to treating disease, and specific therapies.
Several options for licensing Gladstone IP are available to both new start-ups, established companies, and research institutions.
CONTACT
Contact the Corporate Liaison and Ventures Team for more information on licensing opportunities
IP PORTFOLIO
Explore Our IP Portfolio
Latest News
Read
Novel Biosensor Uses DNA ‘Barcodes’ to Uncover Disease Signals in Cells
Inspired by bacterial biology, the Gladstone-developed “Detectron” opens up new possibilities for disease research and potentially treatments.
Read
Meet Gladstone: Ayush Midha
Ayush Midha, a graduate student in the Jain Lab, studies how the body's metabolism adapts to low oxygen—work that's uncovered backup energy pathways, potential fertility treatments, and a link between oxygen levels and tumor growth.
Read
How a Single Viral Protein Hijacks Immune Cells to Supercharge COVID-19 Infection
A new discovery reveals how a SARS-CoV-2 protein reprograms immune cells to accelerate viral spread—and points to a new strategy for therapeutic intervention.
Read
Rethinking ‘Exhausted’ T Cells: Gilbert Herrera Named Inaugural Ellen & Bernard Marson Fellow
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now